May 14 |
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at th...
|
May 7 |
What Makes Shattuck Labs (STTK) a New Buy Stock
|
May 7 |
Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect?
|
May 4 |
Shattuck Labs First Quarter 2024 Earnings: Beats Expectations
|
May 4 |
Shattuck Labs Inc (STTK) Reports First Quarter 2024 Financial Results
|
May 2 |
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates
|
May 2 |
Shattuck Labs GAAP EPS of -$0.37, revenue of $1.11M
|
May 2 |
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
Apr 18 |
Owning 36% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK),
|
Apr 9 |
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
|